(0.16%) 5 247.50 points
(0.17%) 39 603 points
(0.20%) 18 252 points
(0.85%) $79.93
(0.78%) $2.32
(1.47%) $2 374.60
(1.69%) $28.85
(0.69%) $997.60
(0.05%) $0.928
(-0.33%) $10.83
(-0.09%) $0.798
(-0.53%) $92.06
1.12% CNY 1.810
@ CNY1.720
Wydano: 13 vas. 2024 @ 16:31
Zwrot: 5.23%
Poprzedni sygnał: vas. 9 - 17:06
Poprzedni sygnał:
Zwrot: -6.01 %
Live Chart Being Loaded With Signals
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; TJ107, a recombinant human IL-7, which is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial...
Stats | |
---|---|
Dzisiejszy wolumen | 64 650.00 |
Średni wolumen | 282 827 |
Kapitalizacja rynkowa | 139.41M |
EPS | CNY0 ( 2024-03-29 ) |
Last Dividend | CNY0 ( N/A ) |
Next Dividend | CNY0 ( N/A ) |
P/E | -0.730 |
ATR14 | CNY0.00400 (0.22%) |
Wolumen Korelacja
I-Mab Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
ATNX | 0.884 |
CGO | 0.88 |
BPRN | 0.88 |
GFAI | 0.874 |
DRCT | 0.853 |
CFRX | 0.848 |
BELFA | 0.842 |
APLD | 0.84 |
CNTY | 0.838 |
CVCY | 0.834 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
I-Mab Korelacja - Waluta/Towar
I-Mab Finanse
Annual | 2023 |
Przychody: | CNY27.64M |
Zysk brutto: | CNY27.64M (100.00 %) |
EPS: | CNY-16.53 |
FY | 2023 |
Przychody: | CNY27.64M |
Zysk brutto: | CNY27.64M (100.00 %) |
EPS: | CNY-16.53 |
FY | 2022 |
Przychody: | CNY-221.56M |
Zysk brutto: | CNY-248.80M (112.29 %) |
EPS: | CNY-31.75 |
FY | 2021 |
Przychody: | CNY88.03M |
Zysk brutto: | CNY41.59M (47.25 %) |
EPS: | CNY-29.19 |
Financial Reports:
No articles found.
I-Mab
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; TJ107, a recombinant human IL-7, which is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat lymphopenia and cancer immunotherapy; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody for inflammation and CRS-related therapies; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers, as well as TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for solid tumors and TJ-C64B, a tumor-dependent T-cell engager for ovarian and other cancers. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej